Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs

Circulation

Volumn 110, Issue 16, 2004, Pages 2313-2319

  Shiroshita Takeshita, Akiko ^a   Schram, Gernot ^a   Lavoie, Joel ^a   Nattel, Stanley ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b NONE   (Canada)

Author keywords

Antiarrhythmia agents; Antioxidants; Electrophysiology

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CALCIUM CHANNEL L TYPE; SIMVASTATIN; STATINE DERIVATIVE; VITAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATRIAL EFFECTIVE REFRACTORY PERIOD; ATRIOVENTRICULAR BLOCK; CONTROLLED STUDY; DOG; DOWN REGULATION; DRUG EFFECT; ELECTROPHYSIOLOGY; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART VENTRICLE REMODELING; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REFRACTORY PERIOD; SUPRAVENTRICULAR TACHYCARDIA; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; ATRIAL FIBRILLATION; CALCIUM CHANNELS, L-TYPE; CARDIAC PACING, ARTIFICIAL; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; OXIDATIVE STRESS; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SIMVASTATIN; VITAMIN E;

EID: 6444232791     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000145163.56529.D1     Document Type: Article

References (37)

1. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
2. Morillo CA, Klein GJ, Jones DL, et al. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 1995;91:1588-1595.
3. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: electrophysiological remodeling. Circulation. 1996;94:2953-2960.
4. Gaspo R, Bosch RF, Talajic M, et al. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation. 1997;96:4027-4035.
5. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res. 2002;54:347-360.
6. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation. 1999;100:2191-2197.
7. Fareh S, Bénardeau A, Nattel S. Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res. 2001;49:762-770.
8. Shinagawa K, Shiroshita-Takeshita A, Schram G, et al. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insight into the mechanisms of the superior efficacy of amiodarone. Circulation. 2003;107:1440-1446.
9. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104:174-180.
10. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res. 2001;89:e32-e38.
11. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-2891.
12. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006-3010.
13. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci. 2002;23:482-486.
14. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426-431.
15. Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation. 1998;98:2202-2209.
16. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997;81:512-525.
17. Yue L, Melnyk P, Gaspo R, et al. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res. 1999;84:776-784.
18. Brundel BJ, Van Gelder IC, Henning RH, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation. 2001;103:684-690.
19. Brundel BJ, Van Gelder IC, Henning RH, et al. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasc Res. 1999;42:443-454.
20. Goette A, Honeycut C, Langberg JJ. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation. 1996;94:2968-2974.
21. Leistad E, Aksnes G, Verburg E, et al. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation. 1996;93:1747-1754.
22. Daoud EG, Knight BP, Weiss R, et al. Effects of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation. 1997;96:1542-1550.
23. Yu WC, Chen SA, Lee SH, et al. Tachycardia-induced changes of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs. Circulation. 1998;97:2331-2337.
24. Lee SH, Yu WC, Cheng JJ, et al. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation. 2000;101:200-206.
25. + exchanger in short-term atrial electrophysiological remodeling. Circulation. 2000;101:1861-1866.
26. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000;101:1861-1866.
27. +-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res. 2002;54:438-446.
28. Mason RP, Mak IT, Walter MF, et al. Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil. Biochem Pharmacol. 1998;55:1843-1852.
29. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437.
30. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
31. Kureishi Y, Luo Y, Shiojima I, et al. The HMA CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
32. Luo JD, Zhang WW, Zhang GP, et al. Effects of simvastatin on activities of endogenous antioxidant enzyme and angiotensin-converting enzyme in rat myocardium with pressure-overloaded cardiac hypertrophy. Acta Pharmacol Sin. 2002;23:124-128.
33. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A. 1989;86:6377-6381.
34. Takahashi M, Tsuchiya J, Niki E. Scavenging of radicals by vitamin E in the membrane as studied by spin labeling. J Am Chem Soc. 1989;111:6350-6353.
35. Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002;106:2854-2858.
36. Satoh K, Yamato A, Nakai T, et al. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol. 1995;116:1894-1898.
37. Mital S, Zhang X, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol. 2000;279:H2649-H2657.